RT Journal Article
SR Electronic
T1 Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 929
OP 935
DO 10.21873/invivo.12333
VO 35
IS 2
A1 LEON SCHNÖLLER
A1 LUKAS KÄSMANN
A1 JULIAN TAUGNER
A1 REEM ABDO
A1 CHUKWUKA EZE
A1 FARKHAD MANAPOV
YR 2021
UL http://iv.iiarjournals.org/content/35/2/929.abstract
AB Background/Aim: Previous studies have suggested the prognostic value of the Lung Immune Prediction Index (LIPI) and the Gustave Roussy Score (GRIM) as prognostic markers in advanced small cell lung cancer (SCLC). However, LIPI and GRIM score have not been evaluated in patients with limited stage SCLC (LS-SCLC). Patients and Methods: Pretreatment LIPI and GRIM score of 33 (43%) patients out of 77 LS-SCLC patients treated with chemoradiotherapy (CRT) during 2004-2015 were included. Results: The median overall survival (OS) time in the good, intermediate, and poor LIPI subgroups were 14, 17 and 3 months (p=0.973) and 14, 17 and 17 months in the GRIM subgroups. In univariate analysis, patients age <65 years (p=0.008), concurrent chemotherapy (p=0.028), and administering prophylactic cranial irradiation (PCI) (p=0.031) were associated with improved OS. Using Cox regression analysis, age remained significant (HR=3.299, p=0.031) and PCI showed a trend (HR=2.801, p=0.06). Conclusion: Independent predictors of overall survival were identified and can contribute to improved treatment personalization. Concurrent chemotherapy and PCI after CRT were associated with improved OS compared to LIPI- and GRIM-score, which had no prognostic impact in LS-SCLC.